Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Topline results show BROADEN study of Waylivra met primary endpoint

Aug. 7, 2019

Promising new target identified for tissue regeneration

Aug. 7, 2019

Radius initiates phase III wearABLe study of abaloparatide-patch

Aug. 7, 2019

Zydus completes phase III trials of saroglitazar in type 2 diabetes mellitus

Aug. 6, 2019

A spoonful of sugar helps immunity calm down

Aug. 5, 2019

New glucose-lowering compounds presented by Daiichi Sankyo

Aug. 2, 2019

Sickle cell disease: Editing small group of cells leads to big-enough effects

Aug. 1, 2019

MannKind advances pediatric study of Afrezza into final cohort

Aug. 1, 2019

Chipscreen Biosciences presents clinical data for chiglitazar in type 2 diabetes

July 31, 2019

SHH signaling modulation as a promising new therapeutic strategy for ECO syndrome

July 30, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...